Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core US Aggregate Bond ETF (AGG) vs 10X Genomics Inc (TXG) Price & Performance

iShares Core US Aggregate Bond ETF
10X Genomics Inc

Price performance

Price movement over the last 24 hours

Key statistics

iShares Core US Aggregate Bond ETF vs 10X Genomics Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.07, while 10X Genomics Inc trades at $36.87 (market cap $4.80B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.

AGGTXG
Sector
Fixed IncomeHealth
52-Week High
$101.40$40.00
52-Week Low
$97.63$11.34
Market Cap
$4.80B
Enterprise Value
$4.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core US Aggregate Bond ETF

AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.

The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.

10X Genomics Inc

TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.

The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core US Aggregate Bond ETF

AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.

Read more on AGG

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG